CRL 10
Latest Information Update: 18 Apr 2002
Price :
$50 *
At a glance
- Originator Nonindustrial source
- Class Antivirals; Peptides
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Herpes simplex virus infections
Most Recent Events
- 18 Apr 2002 No development reported - Preclinical for Herpes simplex virus infections in Argentina (unspecified route)
- 16 Oct 2000 New profile
- 16 Oct 2000 Preclinical development for Herpes simplex virus infections in Argentina (Unknown route)